HPHyuk Kyoon Park

Hyuk Kyoon Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hyuk Kyoon Park has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Impact of Angiotensin Receptor-Neprilysin Inhibitor Based on Short-Term Treatment Response in Heart Failure

    by Hyuk Kyoon Park, Jong Sung Park, Myeong Seop Kim, Eunkyu Lee, Hyohun Choi, Yoon Jung Park, Bo Eun Park, Hong Nyun Kim, Namkyun Kim, Myung Hwan Bae, et al.

    Aims: The long-term effect of angiotensin receptor–neprilysin inhibitor (ARNI) remains uncertain in patients who have experienced improvements in left ventricular (LV) systolic function or significant LV reverse remodelling following a certain period of treatment. It is also unclear how ARNI performs in patients who have not shown these improvements. This study aimed to assess the impact of prolonged ARNI use compared with angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in patients with and without significant treatment response after 1 year of heart failure (HF) treatment. Methods and results: The present study enrolled patients with HF with reduced ejection fraction (HFrEF) who were treated with either ARNI or ACEIs/ARBs within 1 year of undergoing index echocardiography. After 1 year of treatment, patients were reclassified into the following groups: (i) patients with HF with improved ejection fraction and persistent HFrEF and (ii) patients with and without LV reverse remodelling based on the follow-up echocardiography. The effect of ARNI versus that of ACEIs/ARBs in each group was assessed from the time of categorizing into new groups using the composite event of all-cause mortality and HF hospitalization. A total of 671 patients with HFrEF (age, 66.4 ± 14.1 years; males, 66.8%) were included, and 133 (19.8%) composite events of death and rehospitalization for HF were observed during the follow-up (median follow-up, 44 [interquartile range, 34–51] months). ARNI had a significantly lower event rate than ACEIs/ARBs in patients with HF with improved ejection fraction (7.0% vs. 30.4%, P = 0.020) and those with persistent HFrEF (17.6% vs. 49.7%, P < 0.001). Irrespective of whether patients exhibited LV reverse remodelling (15.8% vs. 31.1%, P = 0.001) or not (15.0% vs. 54.9%, P < 0.001), ARNIs were associated with a significantly lower event rate than ACEIs/ARBs. Conclusions: Regardless of significant treatment response measured by either LVEF or LV reverse remodelling after 1 year of treatment, the extended utilization of ARNI demonstrated a more favourable prognosis than that of ACEIs/ARBs in patients with HFrEF.


  • Open Access

    Predictors of stroke or systemic embolism in patients with non‐valvular atrial fibrillation with CHA2DS2‐VASc score of 0

    by Hyohun Choi, Myung Hwan Bae, Yoon Jung Park, Hyuk Kyoon Park, Eunkyu Lee, Myeong Seop Kim, Jong Sung Park, Hyeon Jeong Kim, Bo Eun Park, Hong Nyun Kim, et al.

    Background: Anticoagulant therapy has been important for stroke prevention in patients with atrial fibrillation (AF). However, it was not recommended due to its relatively higher risk of bleeding than its lower risk of stroke in patients with a CHA2DS2‐VASc score of 0.Hypothesis: This study aimed to evaluate the predictors of stroke in AF patients with very low risk of stroke.Methods: Between 1990 and 2020, 542 patients with non‐valvular AF (NVAF) with a CHA2DS2‐VASc score of 0 followed up for at least 6 months were enrolled. Patients with only being woman as a risk factor were included as a CHA2DS2‐VASc score of 0 in this study. The primary outcome was stroke or systemic embolism.Results: The primary outcome rate was 0.78%/year. In Cox hazard model, age of ≥50 years at diagnosis (hazard ratio [HR] 6.710, 95% confidence interval [CI] 1.811–24.860, p = .004), LVEDD of ≥46 mm (HR 4.513, 95% CI 1.038–19.626, p = .045), and non‐paroxysmal AF (HR 5.575, 95% CI 1.621–19.175, p = .006) were identified as independent predictors of stroke or systemic embolism. Patients with all three independent predictors had a higher risk of stroke or systemic embolism (4.21%/year), whereas those without did not have a stroke or systemic embolism.Conclusion: The annual stroke or systemic embolism rate in NVAF patients with CHA2DS2‐VASc score of 0 was 0.78%/year, and age at AF diagnosis, LVEDD, and non‐paroxysmal AF were independent predictors of stroke or systemic embolism in patients considered to have a very low risk of stroke.


  • Open Access

    Impact of the COVID-19 Pandemic on Patient Delay and Clinical Outcomes for Patients With Acute Myocardial Infarction

    by Hyohun Choi, Jang Hoon Lee, Hyuk Kyoon Park, Eunkyu Lee, Myeong Seop Kim, Hyeon Jeong Kim, Bo Eun Park, Hong Nyun Kim, Namkyun Kim, Se Yong Jang, et al.

    Choi H, et al. J Korean Med Sci. 2022 May;37(21):e167. https://doi.org/10.3346/jkms.2022.37.e167


  • Open Access

    Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City

    by Bo Eun Park, Jang Hoon Lee, Hyuk Kyoon Park, Hong Nyun Kim, Se Yong Jang, Myung Hwan Bae, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Bong Yul Lee, et al.

    Park BE, et al. J Korean Med Sci. 2020 Oct;36(2):e15. https://doi.org/10.3346/jkms.2021.36.e15